No connection

Search Results

Corporate Score 38 Neutral

Sweetgreen Pivots to High-Protein Wraps to Reverse Sales Decline

Apr 21, 2026 10:35 UTC
SG, CAVA
Medium term

Fast-casual chain Sweetgreen is testing a new wrap menu to attract younger demographics and health-conscious consumers. The move comes as the company struggles with declining same-store sales and strategic menu missteps.

  • New wrap menu items priced $11-$15
  • Strategy targets younger demographics and GLP-1 users
  • Effort to move away from declining 'bowl' trend
  • Comparison to Cava's successful steak launch
  • Company facing store closures and piling losses

Sweetgreen (NYSE: SG) is attempting to revitalize its brand and financial performance by introducing high-protein wraps into its menu. The new offerings, currently being tested in select New York City locations, are priced starting at approximately $11 and will remain under $15 across all test markets. The company has faced significant headwinds as the fast-casual segment becomes increasingly competitive, leaving brands squeezed between low-cost fast food and premium casual dining. Sweetgreen has specifically struggled with a decline in same-store sales and a perceived consumer pushback against the 'bowl' trend. Previous attempts to diversify the menu, including the addition of fries, failed to stabilize the company's fortunes, leading to mounting losses and the closure of several locations during lease renewals. This strategic pivot mirrors a successful move by competitor Cava (NYSE: CAVA). After launching a grilled steak option in the second quarter of 2024, Cava saw its same-store sales jump from 2.3% in the first quarter to 14.4% in the second. This momentum continued with comparable-restaurant sales growth reaching as high as 21.2% in subsequent quarters, while average unit volumes climbed to $2.9 million by fiscal Q1 2025. By leveraging existing ingredients in a more trendy, portable format, Sweetgreen aims to capture a younger audience and appeal to those on GLP-1 weight loss medications. While the stock remains speculative given the company's current financial struggles, the success of the wrap strategy could provide a meaningful catalyst for upside potential.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Share this article

Related Articles

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Home
Terminal
AI
Markets
Profile